TETRAPHASE PHARMACEUTICALS I's ticker is TTPHXXXX and the CUSIP is 88165N105. A total of 90 filers reported holding TETRAPHASE PHARMACEUTICALS I in Q1 2017. The put-call ratio across all filers is 0.18 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2016 | $596,000 | +3.1% | 147,819 | -2.0% | 0.00% | 0.0% |
Q3 2016 | $578,000 | -11.1% | 150,906 | -0.1% | 0.00% | 0.0% |
Q2 2016 | $650,000 | +13.8% | 151,120 | +22.5% | 0.00% | 0.0% |
Q1 2016 | $571,000 | -52.9% | 123,353 | +2.0% | 0.00% | -50.0% |
Q4 2015 | $1,213,000 | +35.4% | 120,917 | +0.7% | 0.00% | +100.0% |
Q3 2015 | $896,000 | -87.5% | 120,115 | -20.3% | 0.00% | -88.9% |
Q2 2015 | $7,150,000 | +84.9% | 150,725 | +42.8% | 0.01% | +80.0% |
Q1 2015 | $3,868,000 | +30.4% | 105,568 | +41.4% | 0.01% | +25.0% |
Q4 2014 | $2,966,000 | +132.4% | 74,681 | +16.7% | 0.00% | +100.0% |
Q3 2014 | $1,276,000 | +49.4% | 63,984 | +1.1% | 0.00% | +100.0% |
Q2 2014 | $854,000 | +100.9% | 63,302 | +62.3% | 0.00% | 0.0% |
Q1 2014 | $425,000 | -17.2% | 38,997 | +2.8% | 0.00% | 0.0% |
Q4 2013 | $513,000 | +39.4% | 37,919 | +17.2% | 0.00% | 0.0% |
Q3 2013 | $368,000 | +84.0% | 32,367 | +13.9% | 0.00% | – |
Q2 2013 | $200,000 | – | 28,428 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
HARVEY CAPITAL MANAGEMENT INC | 293,675 | $14,061,000 | 4.76% |
BB BIOTECH AG | 1,507,114 | $71,497,000 | 1.94% |
SECTORAL ASSET MANAGEMENT INC | 893,076 | $42,368,000 | 1.77% |
Opaleye Management Inc. | 65,000 | $3,084,000 | 1.23% |
COLUMBIA PARTNERS L.L.C. INVESTMENT MANAGEMENT | 390,294 | $18,515,000 | 1.14% |
Granite Point Capital Management, L.P. | 75,206 | $3,568,000 | 1.04% |
Granahan Investment Management | 705,601 | $33,474,000 | 0.95% |
Iguana Healthcare Management, LLC | 50,000 | $2,372,000 | 0.75% |
Eventide Asset Management | 290,000 | $13,758,000 | 0.74% |
Rhenman & Partners Asset Management AB | 107,400 | $5,095,000 | 0.61% |